ISDA

Entry Detail

PDB ID:

5SX5

Keywords:

TRANSFERASE/IMMUNE SYSTEM

Title:

Crystal Structure of panitumumab in complex with epidermal growth factor receptor domain 3 mutant S468R.

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Cricetulus griseus

PDB Version:

Deposition Date:

2016-08-09

Release Date:

2016-10-05

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.50 Å

R-Value Free:

0.24

R-Value Work:

0.22

R-Value Observed:

0.22

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Polymer Type:polypeptide(L)
Description:Panitumumab Fab Heavy Chain
Chain IDs:B (auth: J), D (auth: H)
Chain Length:221
Number of Molecules:2
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Description:Panitumumab Fab Light Chain
Chain IDs:A (auth: K), C (auth: L)
Chain Length:214
Number of Molecules:2
Biological Source:Homo sapiens

Protein Blast

Polymer Type:polypeptide(L)
Description:Epidermal growth factor receptor
Chain IDs:E (auth: M), F (auth: N)
Chain Length:201
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P00533 Pfam ID:PF01030 EC:2.7.10.1

Ligand Molecules

1PE

EDO

GOL

SO4

Primary Citation

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance.

Sickmier, E.A, Kurzeja, R.J, Michelsen, K, Vazir, M, Yang, E, Tasker, A.S.Show

Plos One 11 e0163366 e0163366 (2016)

PMID: 27658254 DOI: 10.1371/journal.pone.0163366

Abstact

Panitumumab and cetuximab target the epidermal growth factor receptor for the treatment of metastatic colorectal cancer. These therapies provide a significant survival benefit to patients with metastatic colorectal cancer with wild-type RAS. A single point mutation in the ectodomain of EGFR (S468R) confers acquired or secondary resistance in cetuximab treated patients, which is not observed in panitumumab-treated patients. Structural and biophysical studies presented here show this mutation directly blocks cetuximab binding to EGFR domain III and describes a unique mechanism by which panitumumab uses a central cavity to accommodate this mutation.

Legend

Protein

Chemical

Disease

Primary Citation of related structures